Halogen bonded cocrystals of active pharmaceutical ingredients: pyrazinamide, lidocaine and pentoxifylline in combination with haloperfluorinated compounds

2017/01/01 by Duane Choquesillo‐Lazarte, Vinko Nemec, Dominik Cinčić · 1 voice
Chemistry · #Crystallography and molecular interactions #Crystal structures of chemical compounds #Structural and Chemical Analysis of Organic and Inorganic Compounds

paper · doi:10.1039/c7ce01252g

openalex publication_date 2017/01/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/05/21

Abstract

Six novel halogen-bonded cocrystals of active pharmaceutical ingredients with 1,4-diiodo- and 1,4-dibromotetrafluorobenzene have been synthesized.

Citations

• Mercury CSD 2.0– new features for the visualization and investigation of crystal structures
• OLEX2: a complete structure solution, refinement and analysis program

Discussions

• Halogen bonded cocrystals of active pharmaceutical ingredients: pyrazinamide, lidocaine and pentoxifylline in combination with haloperfluorinated compounds https://doi.org/10.1039/c7ce01252g #Cocrysta [bsky, 0 points, 0 comments]

Related

• Crystal Engineering of Pharmaceutical Cocrystals in the Discovery and Development of Improved Drugs
• Impact of the Coformer Carbon-Chain Length on the Properties of Haloperidol Pharmaceutical Salts
• Chloral Hydrate Polymorphs and Cocrystal Revisited: Solving Two Pharmaceutical Cold Cases
• Stoichiomorphic halogen-bonded cocrystals: a case study of 1,4-diiodotetrafluorobenzene and 3-nitropyridine
• Seeking new polymorphs in pharmaceutical cocrystals: focus on furosemide–ethenzamide